RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Phase of Trial: Phase II/III
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Irinotecan (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms RESILIENT
- Sponsors Ipsen
- 27 Apr 2018 Status changed from not yet recruiting to recruiting.
- 22 Dec 2017 Planned number of patients changed from 482 to 486.
- 22 Dec 2017 Planned End Date changed from 1 Sep 2023 to 1 Dec 2021.